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Genital inflammation is associated with increased HIV acquisition risk. Induction of an
inflammatory response can occur through the recognition of pathogenic or commensal
microbes by Toll-like receptors (TLRs) on various immune cells. We used a in vitro
peripheral blood mononuclear cell (PBMC) system to understand the contribution of
TLR stimulation in inducing inflammation and the activation of target T cells, and its
effect on HIV susceptibility. PBMCs were stimulated with TLR agonists LPS (TLR4),
R848 (TLR7/8), and Pam3CSK4 (TLR1/2), and then infected with HIV NL4-3 AD8.
Multiplexed ELISA was used to measure 28 cytokines in cell culture supernatants. Flow
cytometry was used to measure the activation state (CD38 and HLA-DR), and CCR5
expression on CD4+ and CD8+ T cells. Although TLR agonists induced higher cytokine
and chemokine secretion, they did not significantly activate CD4+ and CD8+ T cells and
showed decreased CCR5 expression relative to the unstimulated control. Despite several
classes of inflammatory cytokines and chemokines being upregulated by TLR agonists,
CD4+ T cells were significantly less infectable by HIV after TLR4-stimulation than the
unstimulated control. These data demonstrate that the inflammatory effects that occur in
the presence TLR agonist stimulations do not necessarily translate to the activation of T
cells. Most importantly, the finding that TLR4-stimulation reduces rather than increases
susceptibility of CD4+ T cells to HIV infection in this in vitro system strongly suggests
that the increased chemokine and possible antiviral factor expression induced by these
TLR agonists play a powerful although complex role in determining HIV infection risk.
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INTRODUCTION
HIV and AIDS is a global epidemic that affects approximately 37 million people worldwide, with
an additional 1.8 million new HIV infections documented in 2017 (1). Sub-Saharan Africa bears
more than half of the global HIV burden, with young adolescent women (aged 15–24 years)
twice as likely to be living with HIV compared to men in this region (1). Furthermore, 75% of
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new HIV infections among adolescents (15–19 years) are in
girls (1). Specifically, South Africa accounts for 19% of HIV
infected people globally, 15% of new HIV infections annually
and 11% of AIDS related deaths worldwide (2). The inception
of antiretroviral therapy (ART) has dramatically reduced the risk
of HIV related morbidity and mortality, and has transformed
the epidemic into a manageable chronic disease (3). Strategies to
prevent infection are crucial for control and eventual eradication
of the HIV epidemic. Various pre-exposure prophylaxis (PrEP)
strategies such as oral tablets, microbicides or intra-vaginal
rings containing anti-retroviral drugs, have been proposed with
various levels of success.
Many social, behavioral and biological factors undermine
the efficacy of these prevention strategies (4–6). One important
biological factor is female genital tract inflammation. Genital
inflammation, defined by the increase in inflammatory and
chemotactic cytokines such as IL-1α, IL-1β, TNF-α, MIP-1α,
MIP-1β, IP-10, and IL-8, among others, has been associated
with an increased risk of HIV acquisition (7–9). One of the
mechanisms implicated is that inflammation increases HIV risk
by causing activation of HIV target cells (CD4+ T cells), thereby
priming the cells for HIV infection (10). Inflammation also leads
to increased recruitment of these activated target CD4+ T cells to
the environment where infection occurs (11). Additionally, T cell
activation profiles in the blood predicted those in the genital tract
(12), suggesting that these activation profiles in the blood could
be a surrogate indication of activation in the genital tract with
subsequent increased risk for HIV. Lastly genital inflammation
leads to the disruption of the mucosal barrier, which is not only
more permissive to viral translocation (11) but also facilitates
infection with less infectious virions (13). Furthermore, genital
inflammation has been shown to reduce the protective effect of
TFV 1% gel as a vaginal microbicide in the CAPRISA 004 trial (6,
14). Additionally, a dysbiotic microbiome or bacterial vaginosis
(BV), which is often associated with genital inflammation (15,
16), also undermined the efficacy of the 1% TFV gel microbicide
(17). The reduced efficacy was attributed to the direct metabolism
of TFV by Gardnerella vaginalis (17), a microbe which is often
associated with BV (18).
Inflammation is the natural biological response for protection
against invading pathogens and damaged tissue. Inflammation
can be broadly defined into three stages; recognition and
release, activation and recruitment, and resolution and repair
(19). The causes of genital inflammation have yet to be fully
understood, however, sexually transmitted infections (STI) and
a dysbiotic microbiome have been implicated (9, 15, 20). The
mechanisms underlying the induction of inflammation by these
two factors likely involve the recognition of pathogen associated
molecular patterns (PAMPs) by Toll-Like Receptors (TLRs)
(21), a cardinal pathway for the induction of an immune
response (22). Various TLRs are able to recognize a broad
range of antigens, from bacterial wall proteins to various
types of bacterial and viral genetic products (23), and each
TLR initiates a distinct signaling cascade for the induction
of innate immune responses (24, 25). TLRs are expressed to
various degrees on most immune cells, with innate antigen
presenting cells expressing the widest range (23). Common
PAMPs that are known to have significant immunological
effects include lipopolysaccharide (LPS) recognized by TLR4
(26, 27), single stranded RNA (ssRNA) recognized by TLR7/8
(28, 29) and bacterial lipopeptides recognized by TLR1/2
(30, 31). TLR-stimulation of mouse splenocytes with R848
(TLR7/8 agonist) increased IL-1α, IL-2 and IL-6 expression,
while LPS increased IL-1α, IL-2 and IL-4 expression (32).
Additionally, Wang et al. demonstrated that human peripheral
blood mononuclear cells (PBMCs) stimulated with LPS induced
the production of IL-1β, TNF-α, IL-6, and IL-22 (32). Similarly
in a study investigating Th17 cell induction in human PBMCs,
the TLR agonists R848 and LPS elicited production of IP-
10, IL-6, MCP-1, IL-8, MIP-1α, and RANTES, while R848
further induced IL-12(p40), IL-1β, and TNF-α production (33).
Furthermore, in the context of vaccine induced immunity,
very similar cytokine responses from human monocyte-derived-
DC’s (MDDCs) and monocyte-derived-macrophages (MDMs)
were found with vaccine adjuvants R848 and the TLR4 agonist
Glucopyranosyl Lipid Adjuvant (GLA) (34). A strong chemokine
response was observed with high expression of MIP-1α, MIP-
1β, RANTES, and IP-10, while the pro-inflammatory cytokine
response was less pronounced, with lower expression of IL-1α,
IL-1β, and TNF-α compared to the chemokines (34).
TLR agonists have been shown to induce potent inflammatory
responses and genital inflammation has been associated with
the increased risk of HIV acquisition. Therefore, we sought
to recapitulate some of the findings from genital inflammation
studies using an in vitro PBMC system to understand the
contribution of TLR-mediated inflammatory response to the
activation and HIV infection of target CD4+ T cells.
MATERIALS AND METHODS
Ethics Statement
This study was carried out in accordance with the
recommendations of the University of KwaZulu-Natal (UKZN)
Biomedical Research Ethics Committee (BREC). All subjects gave
written informed consent in accordance with the Declaration
of Helsinki. The protocol was approved by the UKZN BREC
(BE433/14).
Cell Culture Media
C10 media was used for all cell culture experiments. C10
media consisted of RPMI 1640 with L-glutamine (Lonza,
Basel, Switzerland) containing 10% FCS (non-Hi FCS; Highveld
Biological, JHB, SA), 2% L-glutamine, 1% HEPES, 1% NaPy,
1% NEAA (all from Lonza, Basel, Switzerland). Media was
sterile filtered through the Filtermax 500ml (Techno Plastic
Products, Trasadingen, Switzerland). IL-2 (PeproTech, Rocky
Hill, NJ, USA), was added to C10 media prior to use at a final
concentration of 0.01 µg/ml.
Stimulants and HIV Strain
The TLR agonists LPS (TLR4), R848 (TLR7/8), and Pam3CSK4
(TLR1/2) (all from Invivogen, San Diego, CA, USA)
concentrations were previously optimized in TLR titration
experiments. As no significant differences were observed in
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HIV infections (Supplementary Figure 1) or cytokine profiles
(Supplementary Figures 2–4) between the TLR concentrations,
a final concentration of 2µg/ml was used. Phytohaemagglutinin
(PHA) (Sigma-Aldrich, St. Louis, MO, USA), used as the positive
control at a final concentration of 10µg/ml. Unstimulated
PBMCs were used as the negative control. The CCR5-tropic
HIV-1 NL4-3 AD8 (35) (a gift from Dr. Alex Sigal), was used at a
working dilution of 1:20, which corresponded to an MOI of 0.9,
which had been previously optimized (data not shown). PHA
and unstimulated uninfected conditions were used as controls
for HIV.
Antibodies
Cellular activation was assessed by measurement of HLA-DR
and CD38, similar to previous studies (12, 36, 37). Staining
for flow cytometry was performed both extracellularly and
intracellularly. The extracellular staining cocktail consisted of
LIVE/DEAD Amcyan fixable dye (Thermo Fisher Scientific,
Waltham, MA, USA), anti-CD3-APC-H7, anti-CD4-BV605,
anti-CD8-BV655, anti-CD14-Pacific blue (all from BD
Biosciences, Franklin Lakes, NJ, USA), and anti-CD19-
pacific blue (Biolegend, San Diego, CA, USA). The intracellular
staining cocktail consisted of anti-CCR5-APC, anti-HLA-
DR-PerCP-CY5.5 (all from BD Biosciences, Franklin Lakes,
NJ, USA), anti-CD38-PE-CY7 (Biolegend, San Diego, CA,
USA) and anti-p24-FITC (Beckman Coulter, Brea, CA, USA).
PBMCs were collected at two time-points: day 3 (48 h post
stimulation and prior to HIV infection) and day 5 (48 h
post infection).
Cell Culture
The cell culture and HIV infection protocol used in this
study was adapted from previous studies (38, 39). Blood
was collected from 5 healthy volunteer donors and PBMCs
were isolated by density gradient centrifugation. PBMCs were
resuspended to 1 × 106 cells/ml in C10 media and plated
into cell culture plates. PBMCs were left either unstimulated
(as a negative control) or stimulated immediately after plating
with TLR agonists or PHA, which was used as a positive
control. Following stimulation, the PBMCs were cultured at
37◦C 5% CO2 for 48 h. Following this incubation, the contents
of each well was collected into 15ml falcon tubes and an
aliquot of 500 µl was removed for multiplexed ELISA (culture
supernatants) and flow cytometry (PBMCs) for the day 3 time-
point (post stimulation, prior to HIV infection). The 15ml falcon
tubes were centrifuged, supernatants were discarded, and media
replacement was performed with fresh C10 media. PBMCs were
plated at 1 × 106 cells/ml into 24-well cell culture plates, no
further TLR or PHA stimulations were performed. Subsequently,
HIV infection was done by the addition of 250 µl at a 1:20
dilution of the HIV-1 NL4-3 AD8 viral stocks at a MOI of 0.9.
PHA and unstimulated uninfected wells were treated with 250
µl C10 media. Plates were incubated at 37◦C 5% CO2 for 48 h,
whereupon multiplexed ELISA (culture supernatants) and flow
cytometry (PBMCs) was performed for the day 5 time-point (post
HIV infection).
Flow Cytometry
PBMCs were centrifuged at 3,500 rpm for 5min to pellet the cells
and remove soluble HIV, and the cell culture supernatants were
stored at−80◦C for cytokine quantification. PBMCswere washed
with sterile PBS supplemented with 2% FCS and then stained
with 100µl extracellular staining cocktail, fixed, and then stained
with 100 µl intracellular staining cocktail. Data was acquired by
flow cytometry on a BD LSR Fortessa (BD Biosciences, Franklin
Lakes, NJ, USA). Data analysis was performed using FlowJo
v10.4.1 software (Tree Star, Ashland, OR, USA), according to
the gating strategy (Supplementary Figure 5). For the purpose
of this study we reported on four activation phenotypes and
defined these as the following; The CD38+HLA-DR+ phenotype
was defined as hyper-activated, the CD38+HLA-DR- and CD38-
HLA-DR+ phenotypes were defined as intermediately activated,
and the CD38-HLA-DR- phenotype was defined as resting or
not activated.
Cytokine Quantification
The concentrations of 28 cytokines were assessed from cell
culture supernatants using the Bio-Plex Pro Human Cytokine
Group I 27-Plex Panel (Bio-Rad Laboratories, Hercules, CA,
USA) and the Magnetic Luminex R© Assay IL-1α Singleplex Kit
(Research and Diagnostic (R&D) systems Inc., Minneapolis,
Minnesota, USA) as per manufacturer’s instructions. Data was
acquired on the Bio-Plex R© 200 system (Bio-Rad Laboratories,
Hercules, CA, USA). Optimization of standard curves were
performed automatically using the Bio-Plex manager software
version 6.1 (Bio-Rad Laboratories, Hercules, CA, USA). Values
with coefficients of variation <20% and with observed recoveries
between 70 and 130% were considered reliable. Values that were
below the detectable limit were assigned half of the lowest limit
of detection value (LLOD), while values that were above the
detectable limit were assigned double the highest limited of
detection (HLOD) value.
Statistical Analysis
Statistical analyses and graphical representation of data was
performed using the GraphPad Prism version 7.02 software
for windows (GraphPad Software, La Jolla, CA, USA). For
comparisons of cellular activation markers CD38, HLA-DR on
CD4+ and CD8+ T cells, between stimulated conditions and
the unstimulated control, a repeated measures two-way ANOVA
with a Dunnett’s multiple comparisons test was performed.
Similarly, for CCR5 and cytokine comparisons, an ordinary
one-way ANOVA with Dunnett’s multiple comparison test was
performed. Cellular activation results are displayed as mean
percentage (%) ± standard deviation (SD) of CD4+ or CD8+
T cells. Cytokine data was normalized by Log10 transformation
and is displayed as mean concentration (Log10 pg/ml) ±
standard deviation (SD). To understand the effect of various TLR
agonists on cytokine expression, heat maps were generated by
performing a single linkage hierarchical cluster analysis using
R version 3.3.3 statistical software (R Foundation for Statistical
Computing, Vienna, Austria). Radial spider plots were created
using Microsoft Excel© 2013 software (Microsoft Corporation,
Redmond, WA, USA).
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RESULTS
TLR Stimulation Did Not Result in the
Activation of CD4+ T Cells
Minimal cytotoxic effects were observed with TLR stimulation,
apart from R848 where a significant reduction in cell viability was
observed (Supplementary Figure 6). As highly activated CD4+
T cells have been shown to be preferentially infected (10), we
determined how TLR stimulation impacted on the expression
of the activation markers HLA-DR and CD38 on CD4+ T
cells. TLR stimulation did not induce significant CD4+ T cell
activation compared to the unstimulated control (p > 0.05) at
day 3 (post stimulation, prior to HIV infection) or day 5 (post
infection) (Figure 1). However, when PBMCs were stimulated
with the mitogen PHA, distinct increased cellular activation
was observed, with all three activation phenotypes significantly
increased compared to the unstimulated control on day 3 (p <
0.05). Similarly, on day 5 and irrespective of infection status, PHA
induced significantly elevated expressions of CD38+HLA-DR+
and CD38+HLA-DR-, but not CD38-HLA-DR+ on CD4+ T
cells compared to the unstimulated infected control (p ≤ 0.0001)
(Figure 1B). Representative dot plots of flow cytometric data are
shown in Supplementary Figure 7. Relevant mean± SD for data
depicted in Figure 1 are listed in Supplementary Table 1.
TLR Activation Downregulated CCR5
Expression on CD4+ T Cells
Since CCR5 is a co-receptor for R5-tropic HIV infection, we
determined how TLR activation impacted the expression of
CCR5 by CD4+ T cells. R848 stimulation significantly lowered
CCR5 expression (3.2 ± 1.2% of CD4+ T cells) compared to
the unstimulated control (6.9 ± 2.9% of CD4+ T cells) (p <
0.05), while PHA significantly increased the CCR5 expression
(16.6± 6.9% of CD4+ T cells) (p≤ 0.0001) at day 3 (Figure 1C).
Of note, CCR5 expression was significantly lower in PHA-
stimulated infected condition by day 5 (22.1 ± 7.9% of CD4+ T
cells) compared to the PHA-stimulated but uninfected condition
(29.1 ± 8.6% of CD4+ T cells) (p = 0.0003), although both
conditions had significantly higher CCR5 expression than the
unstimulated but HIV-infected control (8.8 ± 2.9% of CD4+ T
cells) (Figure 1D). Representative dot plots of flow cytometric
data are shown in Supplementary Figure 7.
R848 (TLR7/8) Induced Activation of CD8+
T Cells
As CD8+ T cells are important effector cells and are crucial in
viral control, we sought to assess the effect of TLR activation on
CD8+ T cells. Similar findings were observed in the CD8+ and
CD4+T cells, with no significant activation observed with LPS or
Pam3CSK4 stimulations compared to the unstimulated control
at day 3 (Figure 2A). While there was a significant reduction
of inactivated (CD38-HLA-DR-) CD8+ T cells with R848-
stimulation compared to the unstimulated control (p< 0.01), this
did not translate to a significant increase in any of the activated
phenotypes (Figure 2A). PHA induced significant cellular
activation, with all three activation phenotypes significantly
increased compared to the unstimulated control (p < 0.05) on
day 3 (Figure 2A). On day 5, only R848 significantly increased
the frequency of CD8+ T cells expressing CD38+HLA-DR- (p <
0.05), compared to unstimulated cells (p ≤ 0.0001) (Figure 2B).
PHA, irrespective of infection status, maintained elevated
levels of the activation phenotypes CD38+HLA-DR+ and
CD38+HLA-DR- (p ≤ 0.0001) compared to the unstimulated
infected control (Figure 2B). Representative dot plots of flow
cytometric data are shown in Supplementary Figure 8. Relevant
mean ± SD for data depicted in Figure 2 are listed in
Supplementary Table 2.
TLR-Mediated Reduction of CCR5
Expression on CD8+ T Cells Is Restored
Over Time
CCR5 expression by CD8+ T cells was significantly lower than
the unstimulated control (14.3 ± 7.8% of CD8+ T cells) with
LPS (7.2 ± 3.8% of CD8+ T cells) (p < 0.05), R848 (8.1 ±
3.8% of CD8+ T cells) (p < 0.05) or Pam3CSK4 (6.7 ± 3.2%
of CD8+ T cells) (p < 0.01) on day 3 (Figure 2C). Conversely,
significantly elevated CCR5 expression on CD8+ T cells was
observed with PHA (22.6 ± 7.6% of CD8+ T cells) compared
to the unstimulated control (p < 0.01) on day 3. Only LPS (13.1
± 7.6% of CD8+ T cells) maintained significantly lower CCR5
expression on CD8+ T cells than the unstimulated infected
control (21.6 ± 7.8% of CD8+ T cells) on day 5 (p < 0.05)
(Figure 2D). Representative dot plots of flow cytometric data are
shown in Supplementary Figure 8.
LPS (TLR4) and R848 (TLR7/8) Induced
Strong Inflammatory Cytokine Responses
Unsupervised hierarchical clustering analysis and Radial spider
plots were used to evaluate cytokine production by PBMCs in
response to stimulation with various TLR agonists (Figure 3
and Supplementary Figures 9, 10, respectively). Pam3CSK4
(TLR1/2) did not induce much cytokine production and tended
to cluster closely with the unstimulated conditions, while LPS,
R848, and PHA tended to cluster together, with similarly elevated
inflammatory cytokine profiles. Cytokine induction by these TLR
agonists appeared to be higher at day 3 than day 5 (Figure 3).
TLR4 and TLR7/8 Activation Induced the
Greatest Inflammatory Profile, With TLR7/8
Activation Maintaining Inflammatory
Cytokine Profile
As previous studies have shown that genital inflammation,
defined by increased concentrations of a subset of 12
inflammatory cytokines and chemokines (including IL-1α,
IL-1β, IL-6, IL-7, IL-8, IL-10, TNF-α, IP-10, MIP-1α, MIP-1β,
MCP-1, and GM-CSF), predicted >3-fold increased risk for
HIV acquisition (7), we sought to focus further analysis on
the effect of TLR activation on these cytokines and 4 others
(IL-12p70, IFN-γ, RANTES, and IL-17) that have crucial
immunological roles. Both LPS and R848 induced significant
production of the pro-inflammatory cytokines IL-1α, IL-1β,
IL-6, IL-12p70, IFN-γ, and TNF-α at day 3 (p ≤ 0.0001 and
p ≤ 0.0001, respectively) compared to the unstimulated control
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FIGURE 1 | Activation profiles (A,B) and CCR5 expression (C,D) of CD4+ T cells on day 3 prior to HIV infection (A,C) and day 5 post HIV infection (B,D). PHA was
used at a final concentration of 10µg/ml. TLR agonists were used at a final concentration of 2µg/ml. A repeated measures two-way ANOVA with Dunnett’s multiple
comparisons test was used for immune activation, and an ordinary one-way ANOVA with a Dunnett’s multiple comparisons test for CCR5 expression. Significance is
displayed as *p < 0.05, **p < 0.01, ***p < 0.001, ****p ≤ 0.0001 compared to the unstimulated/unstimulated infected control, unless otherwise shown. Sample size,
n = 5, 4 donors run in quadruplicate, 1 donor run in duplicate.
FIGURE 2 | Activation profiles (A,B) and CCR5 expression (C,D) of CD8+ T cells on day 3 prior to HIV infection (A,C) and day 5 post HIV infection (B,D). PHA was
used at a final concentration of 10µg/ml. TLR agonists were used at a final concentration of 2µg/ml. A repeated measures two-way ANOVA with Dunnett’s multiple
comparisons test was used for immune activation, and an ordinary one-way ANOVA with a Dunnett’s multiple comparisons test for CCR5 expression. Significance is
displayed as *p < 0.05, **p < 0.01, ****p ≤ 0.0001 compared to the unstimulated/unstimulated infected control, unless otherwise shown. Sample size, n = 5, 4
donors run in quadruplicate, 1 donor run in duplicate.
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FIGURE 3 | Unsupervised hierarchical cluster heat map analysis of 28 cytokines measured in cell culture supernatants on day 3 (yellow) and day 5 (brown) from the
unstimulated (red), PHA (blue), LPS (green), Pam3CSK4 (purple), or R848 (orange) conditions. PHA was used at a final concentration of 10µg/ml. TLR agonists were
used at a final concentration of 2µg/ml. Sample size, n = 5, 4 donors run in quadruplicate, 1 donor run in duplicate.
(Figures 4A–F). Pam3CSK4 also elicited significantly elevated
pro-inflammatory cytokines compared to the unstimulated
control (p < 0.001), however these levels were generally lower
than those observed with LPS or R848 (Figures 4A–F).
Although cytokine induction was declining by day 5, pro-
inflammatory cytokines IL-1β and IL-6 remained significantly
elevated in the LPS (p ≤ 0.0001), R848 (p ≤ 0.0001), Pam3CSK4
(p ≤ 0.0001), and PHA conditions (p ≤ 0.0001) compared
to the unstimulated HIV-infected control (Figures 4H,I). IL-
1α was significantly elevated in the R848 and PHA uninfected
conditions (p < 0.05) (Figure 4G), while IFN-γ and TNF-α
were significantly elevated only in the R848 condition (p <
0.05) (Figures 4K,L). Relevant mean ± SD for data depicted in
Figure 4 are listed in Supplementary Table 3.
Potent Chemokine Response to TLR
Activation, With Concomitant
Downregulation of IP-10
At day 3, PHA stimulation or TLR activation with LPS, R848
or Pam3CSK4 significantly increased the levels of chemotactic
cytokines IL-8 (p ≤ 0.0001), MIP-1α (p ≤ 0.0001), MIP-1β (p ≤
0.0001), MCP-1 (p< 0.05), and RANTES (p< 0.05) compared to
the unstimulated control (Figures 5A–C,E,F). Additionally, IP-
10 was significantly increased with PHA stimulation compared to
the unstimulated control (p < 0.01) (Figure 5D). R848 appeared
to be a more potent inducer of IP-10 than either LPS or
Pam3CSK4 (Figure 5D).
At day 5, the chemokines IL-8 and MIP-1α remained
significantly elevated in the LPS (p≤ 0.0001), R848 (p≤ 0.0001),
Pam3CSK4 (p ≤ 0.0001) and PHA conditions (p < 0.001)
compared to the unstimulated infected control (Figures 5G,H).
TLR activation with LPS (p < 0.01), R848 (p ≤ 0.0001), or
Pam3CSK4 (p< 0.001) significantly increased MIP-1β compared
to the unstimulated infected control (Figure 5I). The PHA
infected, but not the uninfected, condition had significantly
increased MIP-1β compared to the unstimulated infected control
(p < 0.01) (Figure 5I). Interestingly, with regards to MIP-1β,
the unstimulated and PHA infected conditions had significantly
greater concentrations than the matched uninfected conditions
(p ≤ 0.0001) (Figure 5I). Concentrations of RANTES were
significantly elevated in the R848 and PHA infected conditions
compared to the unstimulated control (p < 0.05) (Figure 5L).
Conversely, IP-10 concentrations were significantly reduced
in the LPS (p < 0.05), R848 (p < 0.05) and the PHA uninfected
(p < 0.01) conditions compared to the unstimulated infected
control (Figure 5J). Relevant mean ± SD for data depicted in
Figure 5 are listed in Supplementary Table 4.
Potent Induction of IL-17 Response With
TLR Agonists LPS (TLR4), R848 (TLR7/8)
and Pam3CSK4 (TLR1/2)
At day 3, the haematopoietic IL-7 and IL-17 were significantly
elevated following LPS (p < 0.01), R848 (p < 0.01), and
PHA stimulation (p < 0.001) compared to the unstimulated
controls, while only IL-17 was significantly elevated with
Pam3CSK4 (p ≤ 0.0001) (Figures 6A,B). Interestingly, IL-17
increased in a dose-dependent manner with R848 stimulation,
with this effect more prominent at day 3 than day 5
(Supplementary Figure 11). PHA, but not TLR activation,
significantly increased GM-CSF compared to the unstimulated
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FIGURE 4 | Box and Whisker plots showing mean ± SD Log10 concentrations of pro-inflammatory cytokines IL-1α (A,G), IL-1β (B,H), IL-6 (C,I), IL-12p70 (D,J),
IFN-γ (E,K), and TNF-α (F,L) from unstimulated (red), LPS (green), R848 (orange), Pam3CSK4 (purple), and PHA (blue) conditions on day 3 prior to HIV infection (top
box: A–F) and day 5 post HIV infection (bottom box: G–L). TLR agonists were used at a final concentration of 2µg/ml. PHA was used at a final concentration of
10µg/ml. All TLR stimulation conditions were infected. An ordinary one-way ANOVA with a Dunnett’s multiple comparisons test was performed. Significance is
displayed as *p < 0.05, ***p < 0.001, ****p ≤ 0.0001 compared to the unstimulated control. Sample size, n = 5, 4 donors run in quadruplicate, 1 donor run
in duplicate.
control (p < 0.05) (Figure 6C). The anti-inflammatory cytokine
IL-10 was significantly elevated by LPS, R848, Pam3CSK4,
and PHA stimulation compared to the unstimulated control
(p ≤ 0.0001) (Figure 6D).
At day 5, the levels of IL-17 were elevated in the LPS (p
≤ 0.0001), R848 (p < 0.05), Pam3CSK4 (p < 0.001), and
PHA-stimulated and uninfected (p < 0.001) and infected (p
≤ 0.0001) conditions compared to the unstimulated infected
control (Figure 6F). Similarly, IL-10 levels were elevated in the
R848 (p < 0.001), Pam3CSK4 (p < 0.05), and PHA infected (p <
0.01) conditions compared to the unstimulated infected control
(Figure 6H). Relevant mean ± SD for data depicted in Figure 6
are listed in Supplementary Table 5.
TLR-Induced Inflammation Limits HIV
Infection of CD4+ T Cells
We determined the effect of TLR-mediated inflammation on the
susceptibility of CD4+ T cells to R5 tropic HIV infection with
NL4-3 AD8 HIV. Stimulation with LPS (TLR4; p < 0.01), and
R848 (TLR7/8) to a lesser extent, reducedHIV infection of CD4+
T cells compared to unstimulated cells (Figure 7). Pam3CSK4
induced infection similar to that of the unstimulated infected
control. PHA-stimulation resulted in significantly more infection
than all other conditions (p < 0.001), with approximately 25%
of CD4+ T cells infected (Figure 7). Furthermore, using a
combination of TLR agonist and PHA, we found that even in
the presence of hyper activation, stimulation with either LPS or
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FIGURE 5 | Box and Whisker plots showing mean ± SD Log10 concentrations of chemotactic cytokines IL-8 (A,G), MIP-1α (B,H), MIP-1β (C,I), IP-10 (D,J), MCP-1
(E,K), and RANTES (F,L) from unstimulated (red), LPS (green), R848 (orange), Pam3CSK4 (purple), and PHA (blue) conditions on day 3 prior to HIV infection (top box:
A–F) and day 5 post HIV infection (bottom box: G–L). TLR agonists were used at a final concentration of 2µg/ml. PHA was used at a final concentration of 10µg/ml.
All TLR stimulation conditions were infected. An ordinary one-way ANOVA with a Dunnett’s multiple comparisons test was performed. Significance displayed as
*p < 0.05, **p < 0.01, ***p < 0.001, ****p ≤ 0.0001 compared to the unstimulated control. Sample size, n = 5, 4 donors run in quadruplicate, 1 donor run in duplicate.
R848 protected CD4+ T cells from HIV infection (p > 0.0001;
Supplementary Figure 12).
DISCUSSION
The purpose of this study was to identify the effects of TLR
agonists on T cell activation, cytokine responses, and the ability
of HIV to infect CD4+ T cells. TLR stimulation resulted in
limited T cell activation, down-regulation of the CCR5 co-
receptor necessary for HIV entry as well as potent inflammatory
cytokine responses, creating an environment less conducive to
HIV infection of CD4+ T cells.
CD4+ T cells have been shown to express various classes of
TLRs (40), providing the ability to recognize and respond to
TLR agonists. In our study, no significant increase in activation
marker expression was observed for either CD4+ or CD8+ T
cells when stimulated with agonists targeting TLR1/2, 7/8, or
4. It has been demonstrated that TLR receptors require co-
stimulation, needing primary T-cell receptor (TCR) engagement
to induce functional T cell responses (41). This is evident with
the mitogen, PHA, where significant CD4+ T cell activation was
observed following stimulation. PHA is a plant lectin that binds
to carbohydrates on the cell surface, including the TCR, thereby
inducing proliferation and activation of T lymphocytes (42–45).
TLR7/8 agonist R848 induced subtle activation of CD4+ T cells,
possibly due to intracellular recognition of R848 that may have
stimulated an adaptive Th1 immune response even in the absence
of TCR signaling (46). Effector CD8+ T cells are generally highly
reliant on CD4+T cell help for functional andmemory responses
(47). Thus, the modest activation of CD4+ T cells with R848 was
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FIGURE 6 | Box and Whisker plots showing mean ± SD Log10 concentrations of haematopoietic cytokines IL-7 (A,E) and IL-17 (B,F), the growth factor GM-CSF
(C,G), and the anti-inflammatory cytokine IL-10 (D,H) from unstimulated (red), LPS (green), R848 (orange), Pam3CSK4 (purple), and PHA (blue) conditions on day 3
prior to HIV infection (top box: A–D) and day 5 post HIV infection (bottom box: E–H). TLR agonists were used at a final concentration of 2µg/ml. PHA was used at a
final concentration of 10µg/ml. All TLR stimulation conditions were infected. An ordinary one-way ANOVA with a Dunnett’s multiple comparisons test was performed.
Significance is displayed as *p < 0.05, **p < 0.01, ***p < 0.001, ****p ≤ 0.0001 compared to the unstimulated control. Sample size, n = 5, 4 donors run in
quadruplicate, 1 donor run in duplicate.
also observed in the CD8+ T cells, providing further evidence of
a cytotoxic Th1 response. Distinct activation of both CD4+ and
CD8+ T cells was observed with PHA stimulation, likely due to
the robust TCR engagement by PHA.
A distinct inflammatory response was observed when looking
at the cytokine profiles induced by TLR stimulation compared
to the unstimulated control. TLR agonists LPS and R848
elicited potent cytokine storms, similar to previous studies
that showed increases in pro-inflammatory and chemotactic
cytokines after stimulation with these TLR agonists (32–34).
R848 also induced the strongest IFN-γ and IL-12p70 response,
reminiscent of the anti-viral Th1 response (48). Furthermore,
R848 stimulated the prolonged expression of IL-1α, IFN-γ, and
TNF-α, further providing evidence of prolonged inflammatory
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FIGURE 7 | Infection rates (measured by p24 expression) of CD4+ T cells either unstimulated or stimulated with PHA or TLR agonists; LPS (TLR4), Pam3CSK4
(TLR1/2) or R848 (TLR7/8). Each symbol represents a donor, while different shades of each symbol represent repeats for that donor. PHA was used at a final
concentration of 10µg/ml. TLR agonists were used at a final concentration of 2µg/ml. Significance was assessed by two-way ANOVA with Dunnett’s multiple
comparisons test. Significance is displayed as **p < 0.01, ***p < 0.0001 compared to the unstimulated infected control. Sample size, n = 5, 4 donors run in
quadruplicate, 1 donor run in duplicate.
responses associated with the adaptive immune response.
Additionally, cytokines associated with immune modulation,
such as IL-1RA, IL-4, and IL-10 were upregulated, presumably to
prevent a prolonged inflammatory response. These data suggest
that the inflammatory responses associated with LPS and R848
stimulation are regulated through immunomodulatory cytokines
to counteract the exaggerated pro-inflammatory response.
Furthermore, Pam3CSK4-mediated expression of IL-1RA, IL-
4, and IL-10 was much lower than LPS or R848, suggesting
that this TLR agonist induces either a Th2 biased or more
regulatory cytokine response or a less potent Th1 response. This
phenomenon may be in part due to this TLR1/2 agonist being
analogous to gram-positive bacteria, which are generally less
pathogenic and less inflammatory than gram-negative bacteria
(49, 50).
The chemokine responses induced by TLR stimulation were
potent, with prolonged IL-8, MIP-1α and MIP-1β expression.
MIP-1α, MIP-1β, and RANTES are ligands for CCR5 and are
associated with the recruitment of CCR5+ cells (51). In the
female genital tract, these chemokines are important factors
that are associated with increased risk for HIV acquisition
in women (7, 8). Interestingly, MIP-1β was increased in the
unstimulated and PHA infected conditions compared to their
uninfected controls at day 5, suggesting that HIV itself induces
the expression of MIP-1β. Dai and Stevenson (52) similarly
showed that HIV-1 Nef induced the production of MIP-1β (52).
Alternatively, the increased detection of soluble MIP-1β may be
as a result of the competitive binding of HIV to CCR5 precluding
MIP-1β binding. Furthermore, the increased expression of IL-8
and MCP-1 at day 3, which are chemotactic for neutrophils
(53) and monocytes (54) respectively, provides the basis for
the initiation of innate immune responses, which then further
potentiate inflammation. Interestingly, higher prolonged IL-8
levels were observed with the bacterial TLR agonists LPS and
Pam3CSK4 compared to the viral TLR agonist R848, suggesting
that neutrophils would be sufficient for control and clearance of
bacterial infections, whereas viral infections generally require a
Th1 cytotoxic adaptive immune response to prevent infection.
This is supported by the finding that IP-10 was induced at
significantly higher concentrations by R848 than the bacterial
TLR agonists. Compared to the unstimulated control at day 5,
significantly less IP-10 was produced following LPS and R848
stimulation, but not by Pam3CSK4. This further supports the
findings above which allude to the induction of an adaptive Th1
response to TLR7/8 activation, but not TLR1/2, while there is
potential for the initiation of an adaptive response with continued
TLR4 activation.
We found no effect of TLR stimulation on the production of
GM-CSF, which was surprising given the inflammatory response
observed. GM-CSF stimulates granulocyte and macrophage
differentiation (55), which we postulated would be key in the
innate immune response, especially against the bacterial TLR
agonists. However, previous literature suggests that GM-CSF and
TLRs appear to have a complex relationship. While GM-CSF
stimulation is known to downregulate the expression of TLR1,
2 and 4 on human monocytes (56), it has also been shown to
enhance LPS-mediated pro-inflammatory cytokine production in
murine microglia via the upregulation of TLR4 and CD14 (57).
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Similarly, Bauer et al. (58) found that GM-CSF partially restored
TLR-mediated functional responses of monocytes from septic
patients (58). One possibility for blunted GM-CSF responses was
that a PBMC model was used, so the need for GM-CSF may be
lost in this lymphocyte-enriched system.
Th17 cells have an important role to play in the homeostasis
and maintenance of the mucosal barrier (59–62), as well as
increased susceptibility to HIV infection (63, 64). One of the
limitations of this study is that we did not assess the Th17 cells
by flow cytometry, however IL-17, as well as IL-7, are good
surrogate indicators for Th17 cell functions (65–67). In our
study, we found elevated IL-7 in all stimulation conditions, with
the exception of Pam3CSK4, possibly suggesting a dampened
or tolerogenic response to this TLR agonist. Furthermore, IL-
17 was also elevated in all stimulated conditions at both day 3
and day 5. Interestingly, a less potent IL-17 response was seen
at day 5 in R848 stimulated cells than those stimulated with
either LPS or Pam3CSK4. These data suggest that the sensing
of bacterial antigens, analogous to microbial translocation, may
induce a prolonged and potent Th17 response to maintain
homeostasis and integrity of the mucosal barrier. However, the
observed significant dose-dependent increase of IL-17 with R848
stimulation suggests a stronger Th17 response with increased
viral sensing.
Unexpectedly, TLR stimulation did not lead to increased HIV
infection of CD4+ T cells. Initially, we assumed that the lack
of CD4+ T cell activation could explain this observation, given
that activated CD4+ T cells are preferentially and more easily
infected (10, 68). However, in preliminary follow up experiments
we found that even in a hyper activated setting, where PHA in
addition to TLR agonists LPS or R848 were used, HIV infection
rates of CD4+T cells were still lower in the TLR agonist and PHA
conditions compared to the PHA only control, thereby indicating
other mechanisms at play. One possibility for the reduced HIV
infection with LPS or R848 stimulation is through increased CC-
binding chemokines which compete with HIV for CCR5 binding
(69, 70), which was determined as a mechanism of resistance
to R5-tropic viruses in elite controllers (71). This model system
supports the concept of increased CC-binding chemokines
relative to a decrease in CCR5 expression with a concomitant
reduction in HIV infection. Furthermore, activation of TLR4
and TLR7/8, by LPS and R848 respectively, has been shown
to induce type 1 interferons (72), which have potent antiviral
effects and most likely played a role in the observed protection
against HIV infection (73). Similarly, the observed protective
effect suggests the induction of an innate antiviral response (74).
This innate antiviral response likely involves host factors such as
the APOBEC family of proteins, which are known to have nucleic
acid editing functions (75–77), and SAMHD1, known to limit
intracellular deoxynucleoside triphosphates thereby restricting
viral replication (78, 79). This model of TLR stimulation creating
an environment less conducive to HIV infection, is similar to
the findings of inflammation and partial immune activation in
highly exposed sero-negatives (HESN) (80, 81), in contrast to
findings in other HESN cohorts showing immune quiescence
(82). These data highlight the complex and heterogeneous
nature of inflammation and immune activation, that determine
HIV risk.
To further understand the effects of TLR stimulation on
adaptive cellular activation, and address the limitations of this
model system, these experiments could be repeated with the
addition of a TCR stimulant such as anti-CD3/CD28 beads.
Furthermore, we used markers of activation which are more
relevant to assessing chronic immune activation (83). Markers of
acute cellular activation, such as CD69 (83), may have been more
appropriate. Additionally, innate antiviral pathways including
interferon stimulated genes, type 1 interferons, APOBEC and
SAMHD1 should be assessed to determine their potential roles
in the observed protective effect by TLR agonists LPS and
R848. Furthermore, the activation of innate immune cells such
as monocytes and DCs were not assessed, and these could
have provided valuable insight into the mechanisms of a TLR-
mediated immunity. Antigen presenting cells such as DCs,
macrophages andmonocytes are generally the first line of defense
in the recognition of pathogens, and subsequently activate the
adaptive immune responses (84). However, monocytes constitute
approximately 20% of the cell population in PBMCs (85), and
so microbial recognition would have occurred. There was an
overall decrease in cytokines from day 3 to day 5, which is
likely due to the removal of stimulants at day 3 prior to HIV
infection. In future, it will be important to assess HIV infection
rates in the presence of continued TLR stimulation. Furthermore,
we assessed cytokine expression from culture supernatants and
could not distinguish the cellular origin of cytokines. As there
was a lack of T cell activation in TLR-stimulated conditions,
the observed cytokine responses were likely mediated by innate
immune cells such as monocytes and neutrophils. Therefore,
performing intracellular cytokine staining (ICS) for a few key
cytokines would allow better discrimination of the main cells
producing key inflammatory cytokines. Furthermore, ICS would
allow better discrimination of cellular functionality, allowing
clearer assessment of cellular subsets.
While PBMCs may not fully reflect cells in the genital tract
of women, this culture system provides valuable insight into
the mechanisms of TLR-induced inflammation. Additionally,
PBMCs represent circulating cells which are a combination of
peripheral and trafficked cells from the tissue, which better
reflects an in vivo setting compared to depleted or purified
immune cell models or cell lines. Jaspan et al. (12) previously
reported that the extent of T cell activation in blood significantly
predicted activation of these cells at the cervix (12). Ex vivo
samples, such as cervical cells or explants are most biologically
representative, however there are still many difficulties in
obtaining and assessing immunity even in these types of
samples (86–88).
These data highlight the inflammatory effects of TLR agonists
on PBMCs, and the need for TCR engagement to induce
activation of adaptive T cells. These results also provide insight
into the nature of the immune responses elicited by various
TLR agonists, with specific responses induced to particular
pathogenic signals. Together, these data provide important
mechanistic insights for HIV acquisition as the types of immune
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responses induced according to the pathogens or combinations
of pathogens sensed, could govern HIV risk.
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